Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of nanOss Bioactive 3D in the Posterolateral Spine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01829997
Recruitment Status : Completed
First Posted : April 11, 2013
Results First Posted : April 17, 2019
Last Update Posted : April 17, 2019
Sponsor:
Information provided by (Responsible Party):
Pioneer Surgical Technology, Inc.

Tracking Information
First Submitted Date  ICMJE April 8, 2013
First Posted Date  ICMJE April 11, 2013
Results First Submitted Date  ICMJE February 12, 2019
Results First Posted Date  ICMJE April 17, 2019
Last Update Posted Date April 17, 2019
Study Start Date  ICMJE April 2013
Actual Primary Completion Date April 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 8, 2013)
Number of Patients With Fusion [ Time Frame: 12 months ]
Fusion is defined as the presence of bridging trabecular bone and less than 3mm of translational motion and less than 5mm of angular motion.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT01829997 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: March 27, 2019)
  • Number of Participants With Improvement in Quality of Life [ Time Frame: 12 months ]
    Number of participants with improvement in quality of life after surgery using the RAND-36 (a short form health survey). It is a 36 set of easily administered quality of life measures answered by the patient.
  • Number of Participants With Improvement in Pain Scores [ Time Frame: 12 months ]
    Number of participants with improvement in pain scores after surgery using the Visual Analog Scale. The scale measured from (0) no pain to (10) unbearable pain.
  • Number of Participants With Decreased Usage of Pain Medication [ Time Frame: 12 months ]
    Number of participants with decreased usage of pain medication after surgery
  • Returning to Work [ Time Frame: 12 Months ]
    Time frame in which patient returned to work after surgery
  • Satisfaction With Surgery [ Time Frame: 12 months ]
    Overall satisfaction with the procedure
Original Secondary Outcome Measures  ICMJE
 (submitted: April 8, 2013)
  • Number of participants with improvement in physical disability [ Time Frame: 12 months ]
  • Number of Participants With Improvement in Quality of Life [ Time Frame: 12 months ]
  • Number of Participants With Improvement in Pain Scores [ Time Frame: 12 months ]
  • Number of Participants With Decreased Usage of Pain Medication [ Time Frame: 12 months ]
  • Returning to Work [ Time Frame: 12 Months ]
  • Satisfaction With Surgery [ Time Frame: 12 months ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Assessment of nanOss Bioactive 3D in the Posterolateral Spine
Official Title  ICMJE A Prospective, Post-Market Assessment Of NanOss Bioactive 3D in the Posterolateral Spine
Brief Summary

Spine fusion is one of the most common procedures performed in spinal surgery. Several surgical techniques can achieve a solid union, but the intertransverse posterolateral fusion (PLF) is the most widely used. However, complications can develop when the bone graft material used is insufficient to achieve the desired fusion. With its unique properties, nanOss Bioactive 3D can be mixed with bone marrow aspirate (BMA) and autograft bone to obtain new bone growth during the healing process.

nanOss Bioactive 3D is approved for use in the U.S., however, additional information is useful to assess its efficacy in the posterolateral spine. The purpose of this study is to assess fusion results in the posterolateral spine using nanOss Bioactive 3D mixed with autograft bone and BMA. It is hypothesized that the use of nanOss Bioactive 3D will result in fusion at 12 months, with CT evidence of bridging trabecular bone, less than 3mm of translational motion, and less than 5 degrees of angular motion.

Detailed Description

The post market clinical investigation is designed to assess instrumented PLF using nanOss Bioactive 3D bone void filler with autograft bone and bone marrow aspirate in patients with symptomatic spinal stenosis secondary to degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis at one or two adjacent levels from L2-S1 characterized by the inclusion and exclusion criteria.

Patients will be evaluated at Preop, discharge, 6 and 12 months. X-rays will be obtained at each visit; Additionally, a CT scan will be performed at the 12 month postoperative visit to assess fusion status.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Degenerative Disc Disease
  • Spinal Stenosis
  • Spondylolisthesis
Intervention  ICMJE Device: nanOss Bioactive 3D BVF
nanOss Bioactive 3D BVF, combined with autograft and bone marrow aspirate, used in the posterolateral spine between L2 and S1. Instrumentation is required. Interbody fusion with PEEK device and autograft may or may not be performed.
Study Arms  ICMJE Experimental: nanOss Bioactive 3D BVF
Bilateral, instrumented posterolateral fusion surgery where nanOss Bioactive 3D will be hydrated with autologous BMA and placed bilaterally on a bed of local autograft bone spanning the transverse processes of the treated segment. If an interbody fusion is performed, only a PLIF or TLIF with PEEK IBF devices may be performed.
Intervention: Device: nanOss Bioactive 3D BVF
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 7, 2018)
22
Original Estimated Enrollment  ICMJE
 (submitted: April 8, 2013)
50
Actual Study Completion Date  ICMJE April 2018
Actual Primary Completion Date April 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • At least 21 years of age and skeletally mature.
  • Symptomatic spinal stenosis secondary to DDD with up to Grade 1 spondylolisthesis at one or two adjacent levels from L2-S1 requiring instrumented PLF surgery.
  • Completed a minimum of 6 months of non-operative treatment.
  • Pre-operative objective evidence of primary diagnosis confirmed by appropriate imaging studies (AP, Lateral, Flexion and Extension images and an MRI or CT scan).
  • Is willing and able to return for post-treatment exams according to the follow-up called for in the protocol.
  • Is able to review, understand and sign the informed consent document.

Exclusion Criteria:

  • Symptomatic at more than two levels.
  • Has had previous fusion surgery at the level(s) to be treated (previous discectomy, laminotomy, laminectomy or nucleolysis at the level(s) to be treated < 6 months ago is ok).
  • Has > 11 degrees lumbar scoliosis.
  • Has > 40 BMI.
  • Has > Grade 1 spondylolisthesis.
  • Has osteoporosis (T-score of -2.5 or below), osteomalacia, Paget's disease or metabolic bone disease.
  • Has a disease that significantly inhibits bone healing (e.g., diabetes type 1, renal failure, impaired calcium metabolism).
  • Has a medical condition that requires or has a history of chronic steroid use (i.e., oral steroids), with the exception of inhaled/nasal corticosteroids steroids or has any medical condition that requires treatment with drugs known to interfere with bone healing.
  • Has a neurological disease (e.g., Parkinson's disease), a psychosocial disorder (e.g., suicidal, diminished capacity) or has a history of substance abuse which would preclude accurate evaluation or limit the ability to comply with study requirements.
  • Has either an active infection or infection at the site of surgery
  • Has a systemic disease (e.g., AIDS, HIV, active hepatitis, tuberculosis)
  • Has rheumatoid arthritis or other autoimmune disease.
  • Has spinal tumors.
  • Has an active malignancy (except non-melanoma skin cancer) or history of any invasive malignancy unless treated and in remission for at least five years.
  • Has a known sensitivity or allergies to porcine collagen, PEEK, tantalum or titanium.
  • Has active arachnoiditis.
  • Has fractures of the epiphyseal plate or fractures for which stabilization of the fracture is not possible.
  • Is a prisoner.
  • Is involved in spinal litigation at the treated level(s).
  • Is participating in another clinical study that would confound Study data.
  • Is pregnant or is interested in becoming pregnant while participating in the Study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 21 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01829997
Other Study ID Numbers  ICMJE NB3D012012
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Pioneer Surgical Technology, Inc.
Study Sponsor  ICMJE Pioneer Surgical Technology, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Stephen Robbins, MD Milwaukee Spinal Specialists
PRS Account Pioneer Surgical Technology, Inc.
Verification Date March 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP